About 4.5 million adults in the United States have psoriasis,1 a chronic, often uncomfortable and disfiguring disease
typically lasting more than 30 years. Approximately half a million individuals
find the disease a substantial problem in everyday life. Fewer than half of
those affected by psoriasis find their treatment highly satisfactory.1
Although available treatment options for patients with severe psoriasis
have changed little over nearly 20 years, psoriasis has recently become a
focus for innovative therapies. With the development of monoclonal antibodies
that alter immune function, 4 new products—2 antibodies that modulate
T-cell functions (efalizumab and alefacept) and 2 tumor necrosis factor α
inhibitors (infliximab and etanercept)—have demonstrated beneficial
effects on moderate to severe psoriasis. In this issue of THE JOURNAL, Gordon
et al2 report on the effect of efalizumab on
psoriasis as measured by both physician and patient assessment. This and other
studies demonstrate that efalizumab is superior to placebo.2- 4 To
determine the place of efalizumab in the current therapeutic armamentarium,
however, its safety and efficacy must be determined relative to other therapies
for severe psoriasis.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 23
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.